This page is part of the FHIR Specification (v1.0.2: DSTU 2). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R4 R3 R2
Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.
<ValueSet xmlns="http://hl7.org/fhir"> <id value="v3-substanceAdminSubstitution"/> <meta> <lastUpdated value="2015-07-31T00:00:00.000+10:00"/> <profile value="http://hl7.org/fhir/StructureDefinition/valueset-shareable-definition"/> </meta> <text> <status value="generated"/> <div xmlns="http://www.w3.org/1999/xhtml"> <p>Release Date: 2015-07-31</p> <p>OID for code system: 2.16.840.1.113883.5.1070</p> <h2>Description</h2> <p> Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided. <br/> </p> <hr/> <table class="grid"> <tr> <td> <b>Level</b> </td> <td> <b>Code</b> </td> <td> <b>Display</b> </td> <td> <b>Definition</b> </td> </tr> <tr> <td>1</td> <td> <span style="color: grey"> <i>(_ActSubstanceAdminSubstitutionCode)</i> </span> </td> <td> <a name="_ActSubstanceAdminSubstitutionCode"> </a> </td> <td> Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects. <br/> </td> </tr> <tr> <td>2</td> <td> E <a name="E"> </a> </td> <td>equivalent</td> <td> Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product. <br/> </td> </tr> <tr> <td>3</td> <td> EC <a name="EC"> </a> </td> <td>equivalent composition</td> <td> Description: <br/> Substitution occurred or is permitted with another product that is a: <br/> pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: <br/> Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril </td> </tr> <tr> <td>4</td> <td> BC <a name="BC"> </a> </td> <td>brand composition</td> <td> Description: <br/> Substitution occurred or is permitted between equivalent Brands but not Generics <br/> Examples: <br/> Zestril for Prinivil Coumadin for Jantoven </td> </tr> <tr> <td>4</td> <td> G <a name="G"> </a> </td> <td>generic composition</td> <td> Description: Substitution occurred or is permitted between equivalent Generics but not Brands <br/> Examples: <br/> Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp) </td> </tr> <tr> <td>3</td> <td> TE <a name="TE"> </a> </td> <td>therapeutic alternative</td> <td> Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. <br/> Examples: <br/> ranitidine for Tagamet </td> </tr> <tr> <td>4</td> <td> TB <a name="TB"> </a> </td> <td>therapeutic brand</td> <td> Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics <br/> > Examples: <br/> Zantac for Tagamet </td> </tr> <tr> <td>4</td> <td> TG <a name="TG"> </a> </td> <td>therapeutic generic</td> <td> Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands <br/> > Examples: <br/> Ranitidine for cimetidine </td> </tr> <tr> <td>2</td> <td> F <a name="F"> </a> </td> <td>formulary</td> <td> Description: This substitution was performed or is permitted based on formulary guidelines. <br/> </td> </tr> <tr> <td>2</td> <td> N <a name="N"> </a> </td> <td>none</td> <td> No substitution occurred or is permitted. <br/> </td> </tr> </table> </div> </text> <url value="http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution"/> <version value="2015-07-31"/> <name value="v3 Code System substanceAdminSubstitution"/> <status value="active"/> <experimental value="false"/> <publisher value="HL7, Inc"/> <contact> <telecom> <system value="other"/> <value value="http://hl7.org"/> </telecom> </contact> <date value="2015-07-31"/> <description value=" Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided."/> <codeSystem> <extension url="http://hl7.org/fhir/StructureDefinition/valueset-oid"> <valueUri value="urn:oid:2.16.840.1.113883.5.1070"/> </extension> <system value="http://hl7.org/fhir/v3/substanceAdminSubstitution"/> <caseSensitive value="true"/> <concept> <code value="_ActSubstanceAdminSubstitutionCode"/> <abstract value="true"/> <display value="ActSubstanceAdminSubstitutionCode"/> <definition value="Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects."/> <concept> <code value="E"/> <abstract value="false"/> <display value="equivalent"/> <definition value="Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product."/> <concept> <code value="EC"/> <abstract value="false"/> <display value="equivalent composition"/> <definition value="Description: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril"/> <concept> <code value="BC"/> <abstract value="false"/> <display value="brand composition"/> <definition value="Description: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven"/> </concept> <concept> <code value="G"/> <abstract value="false"/> <display value="generic composition"/> <definition value="Description: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)"/> </concept> </concept> <concept> <code value="TE"/> <abstract value="false"/> <display value="therapeutic alternative"/> <definition value="Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet"/> <concept> <code value="TB"/> <abstract value="false"/> <display value="therapeutic brand"/> <definition value="Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics > Examples: Zantac for Tagamet"/> </concept> <concept> <code value="TG"/> <abstract value="false"/> <display value="therapeutic generic"/> <definition value="Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands > Examples: Ranitidine for cimetidine"/> </concept> </concept> </concept> <concept> <code value="F"/> <abstract value="false"/> <display value="formulary"/> <definition value="Description: This substitution was performed or is permitted based on formulary guidelines."/> </concept> <concept> <code value="N"/> <abstract value="false"/> <display value="none"/> <definition value="No substitution occurred or is permitted."/> </concept> </concept> </codeSystem> </ValueSet>
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.